Disease Landscape and Forecast Insights

The Emerging Biosimilars Landscape offers extensive coverage of the global biosimilars development landscape. We track over 726 currently available and novel biosimilar products, detailing…

Doublet or triplet chemotherapy alone or in combination with angiogenesis inhibitors remains the cornerstone of treatment for metastatic colorectal cancer. Patients without RAS mutations also…

The multibillion dollar non-Hodgkin’s lymphoma (NHL) / chronic lymphocytic leukemia (CLL) therapy market is dynamic and experiencing substantial growth. The covalent BTK inhibitors ibrutinib (…

Acute coronary syndrome (ACS) encompasses acute ST-elevation myocardial infarction, non-ST-elevation myocardial infarction, and unstable angina. ACS is a significant cause of morbidity and…

Immune checkpoint inhibitors have transformed many oncology settings since their entry into the marketplace just over a decade ago. They are continuing to advance into earlier lines of therapy,…

The acceptance of Roche / Chugai’s nonfactor bispecific antibody Hemlibra as a key treatment for hemophilia A has changed the treatment landscape. Hemlibra has been transformative for many…

Atrial fibrillation (AF) is an abnormal heart rhythm characterized by rapid and irregular beats of the atrial chambers of the heart. AF is the most common arrhythmia treated in clinical practice…

The market for metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH), has great untapped potential owing to the disease’s high…

Clarivate Epidemiology’s coverage of Dup15q syndrome comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany…

The rising rates of antimicrobial resistance (AMR) have created an emergent need for development and discovery of antibiotics with activity against drug-resistant gram-negative pathogens (GNPs)…

Clarivate Epidemiology’s coverage of polycythemia vera (PV) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France,…

The PsA therapy market has become highly dynamic with the recent launches of targeted agents such as AbbVie’s Rinvoq and Skyrizi and UCB’s bimekizumab. Upcoming launches in the next few years will…